Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.385 AUD | +8.45% | +6.94% | +11.59% |
Apr. 18 | Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761 | CI |
Apr. 18 | Immutep Taps Center for Human Drug Research for IMP761 Human Clinical Trial | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.59% | 272M | |
+2.65% | 42.11B | |
+48.83% | 40.08B | |
+8.04% | 40B | |
-10.82% | 26.87B | |
+7.63% | 24.58B | |
-23.87% | 18.44B | |
+1.52% | 11.94B | |
+31.73% | 11.66B | |
+7.38% | 11.01B |
- Stock Market
- Equities
- IMM Stock
- News Immutep Limited
- Immutep Reports 'Compelling' Data from Mid-Stage Lung Cancer Trial; Shares Rise Midday